Development
Cullinan Therapeutics, Inc.
CGEM
$8.08
$0.141.76%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.95% | 11.00% | 21.96% | 34.00% | 38.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.95% | 36.01% | 36.39% | 59.38% | 52.41% |
| Operating Income | -43.95% | -36.01% | -36.39% | -59.38% | -94.89% |
| Income Before Tax | -211.83% | -208.51% | -194.53% | 223.94% | 324.22% |
| Income Tax Expenses | -133.53% | -104.22% | -109.42% | 415.25% | -- |
| Earnings from Continuing Operations | -242.04% | -253.44% | -230.93% | 178.18% | 261.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -3.96% | -85.76% | -86.49% | -66.56% | 5.43% |
| Net Income | -237.72% | -248.03% | -225.52% | 184.22% | 269.61% |
| EBIT | -43.95% | -36.01% | -36.39% | -59.38% | -94.89% |
| EBITDA | -43.82% | -35.84% | -36.26% | -59.31% | -94.91% |
| EPS Basic | -248.40% | -259.79% | -235.45% | 175.57% | 265.60% |
| Normalized Basic EPS | -47.21% | -37.16% | -36.43% | -58.98% | -83.24% |
| EPS Diluted | -257.11% | -269.89% | -243.62% | 168.18% | 256.72% |
| Normalized Diluted EPS | -48.54% | -38.38% | -37.74% | -57.86% | -81.60% |
| Average Basic Shares Outstanding | -8.03% | -5.29% | -2.49% | 1.21% | 4.82% |
| Average Diluted Shares Outstanding | -8.79% | -6.08% | -3.32% | 2.07% | 5.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |